Last updated: June 14, 2026
DESOWEN (desonide) suppliers: who manufactures, markets, and distributes the product in major markets?
DESOWEN is a topical corticosteroid brand whose supply chain is driven by the underlying desonide active pharmaceutical ingredient (API) market, finished-dose manufacturing for creams/ointments, and regional brand marketing distributors. This analysis is not able to produce a complete, accurate “supplier list” for DESOWEN because the necessary source data (confirmed finished-product marketing authorization holders, labeled manufacturers by market, and current distribution entities) is not present in the available input.
What companies supply DESOWEN desonide cream or ointment to wholesalers?
A defensible supplier map requires, by jurisdiction, the labeled manufacturer(s) on the product pack/SmPC, the marketing authorization holder, and the responsible wholesaler/distributor. Those data are not provided here.
Which finished-dose forms matter for supply (cream vs ointment vs gel)?
Supplier identification is form-specific because contract manufacturers often differ by dosage form, strength, and packaging configuration. Without the product’s labeled form/strength and jurisdictional regulatory references, a precise supplier roster cannot be compiled.
Which firms manufacture the DESOWEN active ingredient desonide (API)?
API supplier identification is typically handled via confidential supply, DMF cross-references, and procurement disclosures. A validated API manufacturer list cannot be generated from the provided input alone.
How does desonide API procurement affect finished-product suppliers?
Finished-dose manufacturers commonly qualify multiple API sources, but the exact approved suppliers are controlled by regulatory filings and quality agreements. Without access to those filings, the supplier set cannot be stated accurately.
Who holds the marketing authorization for DESOWEN, by country?
Marketing authorization holders and regional distributors are the practical “suppliers” for customers buying the branded medicine through regulatory and tender channels. The country-by-country holder roster is not available in the input.
Are there different holders for the same brand across EU, UK, and other markets?
Yes. Many topical corticosteroid brands have multiple regional holders tied to tender supply and local labeling obligations. A correct answer requires jurisdiction-specific regulatory references.
What is the Orange Book status of DESOWEN (desonide) and how does it affect supply?
The US Orange Book is relevant for NDAs and ANDAs. DESOWEN is a marketed topical corticosteroid, but the required US listing identifiers (application type, NDA/ANDA number, holder, dosage form entries) are not provided here, so the Orange Book status cannot be determined.
Do generics compete directly with DESOWEN in the same dosage form?
Topical corticosteroid generics may match strength and base, but substitution depends on FDA listing and state-level pharmacy substitution rules. A “direct competitors” mapping needs specific FDA product and strength entries, which are not supplied.
Which generic or private-label desonide products compete with DESOWEN?
Competitive supply depends on which desonide formulations are authorized in a given market, and whether DESOWEN is cream, ointment, or both. Without market and strength details, competing supplier identification would be speculative.
What patent estate risks change DESOWEN supply (Paragraph IV, exclusivity, reformulations)?
The question of patent-related supply shifts requires the DESOWEN patent family and legal status (listed patents by product, expiration dates, and any ANDA litigation). Those inputs are not available here.
How do formulation patents and manufacturing-process patents affect contract manufacturing?
They can restrict “same base” manufacturing changes and impose design-around requirements, but the specific patent set for DESOWEN cannot be enumerated from the provided prompt.
What FDA regulatory pathway status matters for DESOWEN supply?
Topical corticosteroids are usually approved via an NDA, and generics via an ANDA. A pathway-specific supplier list needs the application numbers and the labeled drug product manufacturer(s), which are not provided.
Is DESOWEN an OTC or Rx product and does that change distribution?
OTC status can increase distributor breadth, while Rx supply can concentrate through channel relationships. DESOWEN’s status by jurisdiction is not included in the input.
How can purchasers validate DESOWEN suppliers for procurement or sourcing?
A validated procurement list typically includes:
- labeled drug product manufacturer(s) on the carton/leaflet
- marketing authorization holder (MAH) or NDA holder
- current wholesaler/distributor through tender and logistics records
- lot release partner and quality unit contact points
Those artifacts are not present in the input, so a supplier list cannot be produced.
Key Takeaways
- A precise “suppliers for DESOWEN” roster requires jurisdictional regulatory labeling data (MAH and labeled manufacturer for each dosage form/strength) and/or reliable market distribution records.
- The provided input does not include the required identifiers to generate a complete, accurate supplier list.
FAQs
- Who is the marketing authorization holder for DESOWEN in the UK and EU?
- Which companies contract-manufacture desonide topical creams and ointments?
- Does DESOWEN face competition from generic desonide in the same dosage form?
- How do patent expirations and exclusivity affect DESOWEN’s supply chain?
- What wholesalers distribute DESOWEN to pharmacies and hospitals in major markets?
References
(No sources were provided in the input, and no citations can be generated without verifiable references.)
